JAK2 V617F Mouse Protein Expression Level Determination

JAK2 V617F mouse protein expression level determination is a specialized analytical service for quantifying total and phosphorylated Janus kinase 2 in genetically engineered mouse models of myeloproliferative neoplasms. Accurate measurement of JAK2 V617F protein expression and downstream JAK-STAT signaling provides essential insights into disease mechanisms, pharmacodynamic responses, and the efficacy of JAK inhibitor therapies. This article outlines the sample types, testing panels, analytical platforms, and research applications that support preclinical JAK2-driven disease studies.

Technical Overview

The JAK2 V617F mutation is a somatic gain-of-function alteration in exon 14 of the Janus kinase 2 gene, in which a valine residue at position 617 is substituted by phenylalanine. This substitution occurs within the pseudokinase (JH2) domain and disrupts its autoinhibitory interaction with the catalytic JH1 domain, resulting in constitutive kinase activity. Persistent activation of the JAK2-STAT signaling axis drives aberrant proliferation and survival of hematopoietic progenitor cells and is a defining molecular event in Philadelphia chromosome-negative myeloproliferative neoplasms (MPNs), including polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

Mouse models harboring the JAK2 V617F mutation, including knock-in strains, human transgenic lines, and retroviral bone marrow transplantation models, faithfully recapitulate key human disease features such as erythrocytosis, leukocytosis, splenomegaly, and progressive myelofibrosis. Quantitative determination of JAK2 V617F protein expression levels in these models is therefore critical for characterizing disease progression, evaluating target engagement, and interpreting therapeutic outcomes in preclinical studies.

Our JAK2 V617F mouse protein expression determination service delivers quantitative, reproducible, and publication-ready data using validated antibody-based and mass spectrometry-based platforms, supported by rigorous quality control and standardized sample handling procedures.

Testing Samples

Peripheral Blood

Peripheral blood is collected from the tail vein, retro-orbital sinus, or cardiac puncture under approved animal welfare protocols. Whole blood can be processed into plasma or serum for soluble analyte analysis, while peripheral blood mononuclear cells and total leukocyte fractions are lysed for intracellular protein quantification. Peripheral blood sampling enables longitudinal monitoring of protein expression dynamics within the same animal across multiple time points.

Bone Marrow Cells

Bone marrow is harvested by flushing femurs and tibias with cold PBS, followed by red blood cell lysis and, when required, enrichment of mononuclear cells by density gradient centrifugation. As the primary site of malignant hematopoiesis in JAK2 V617F-driven disease, bone marrow provides the most clinically relevant cellular material for evaluating total JAK2 protein abundance and pathway activation.

Spleen and Liver Tissues

Splenomegaly and extramedullary hematopoiesis are hallmark features of JAK2 V617F mouse models, making the spleen a critical analytical tissue. Spleen and liver specimens are divided for parallel analyses: fresh-frozen portions are used for protein extraction and Western blotting or ELISA, while formalin-fixed paraffin-embedded sections are reserved for immunohistochemical localization of JAK2 and phosphorylated signaling intermediates.

Sorted Hematopoietic Cell Populations

For lineage-specific investigations, hematopoietic stem cells, megakaryocyte-erythroid progenitors, common myeloid progenitors, granulocyte-macrophage progenitors, and mature lineage-positive cells can be isolated by fluorescence-activated cell sorting prior to lysis. This approach enables high-resolution mapping of JAK2 V617F expression and signaling intensity across defined stages of hematopoietic differentiation.

Cell Culture and Transplantation-Derived Samples

Cell lines engineered to express murine or human JAK2 V617F, as well as donor-derived cells from bone marrow transplantation experiments, are also accepted. These samples support in vitro mechanistic studies and ex vivo drug response assays.

Testing Items

The standard testing panel covers the core signaling components of the JAK2 pathway, with customizable extensions to meet specific study objectives:

• Total JAK2 protein quantification, including total mutant and wild-type JAK2 signal
• JAK2 V617F mutant-specific protein detection, where mutation-discriminating reagents or targeted mass spectrometry are applicable
• Phosphorylated JAK2 (Tyr1007/Tyr1008) as a direct readout of kinase activation
• Downstream signaling markers, including phosphorylated STAT5 (Tyr694), phosphorylated STAT3 (Tyr705 and Ser727), phosphorylated ERK1/2, and phosphorylated AKT
• Negative feedback regulators such as SOCS1, SOCS3, and CIS for pathway regulation studies
• Housekeeping normalization proteins, including beta-actin, GAPDH, and alpha-tubulin
• Hematopoietic and inflammatory cytokines, including erythropoietin, thrombopoietin, IL-6, and related soluble biomarkers
• Optional companion assays, including JAK2 V617F allele burden by quantitative PCR or digital PCR for integrated genotype-protein interpretation

Testing Methods

Western Blotting

Western blotting remains the reference method for assessing JAK2 V617F protein expression and phosphorylation status. Samples are lysed in RIPA buffer with protease and phosphatase inhibitors, separated by SDS-PAGE, transferred onto PVDF membranes, and probed with validated primary antibodies. Chemiluminescent or fluorescent detection is followed by quantitative densitometry, with results normalized to housekeeping proteins and expressed relative to matched wild-type controls.

Quantitative ELISA and Multiplex Immunoassays

Sandwich ELISA and bead-based multiplex platforms (such as Luminex) provide high-throughput, absolute quantification of JAK2 protein and phosphorylated signaling proteins from limited sample volumes. These assays are well suited for large cohort studies, dose-response evaluations, and repeated-measurement pharmacodynamic designs requiring picogram-level sensitivity.

Flow Cytometry and Phospho-Flow Cytometry

Intracellular flow cytometry enables single-cell quantification of total and phosphorylated JAK2 and STAT proteins in defined hematopoietic subsets. Multiparameter panels combining surface lineage markers with phospho-specific antibodies reveal cell-type-specific pathway activation heterogeneity without requiring cell sorting.

Immunohistochemistry and Immunofluorescence

IHC and IF performed on spleen, liver, and bone marrow sections localize JAK2 expression and STAT phosphorylation within intact tissue architecture. This approach is particularly valuable for documenting extramedullary hematopoiesis, megakaryocyte clustering, and reticulin fibrosis in disease progression and treatment studies.

Capillary Electrophoresis Immunoassay

Automated capillary-based immunoassay systems, such as Simple Western platforms, offer automated, low-sample-input protein quantification with high reproducibility. This method is recommended when sample material is scarce, such as sorted progenitor populations, or when many conditions must be compared.

Targeted LC-MS/MS Proteomics

Targeted liquid chromatography-tandem mass spectrometry using stable isotope-labeled reference peptides enables absolute quantification of JAK2 protein and, through mutation-specific peptides spanning the V617F junction, direct differentiation of mutant and wild-type protein species. This orthogonal, antibody-independent strategy provides the highest analytical specificity for mutant protein quantification.

Applications

JAK2 V617F mouse protein expression determination supports a broad spectrum of preclinical and translational research objectives:

• Mechanistic investigation of JAK2 V617F-driven myeloproliferative disease initiation, progression, and myelofibrotic transformation
• Pharmacodynamic evaluation of JAK inhibitors such as ruxolitinib, fedratinib, and pacritinib, including target engagement and pathway suppression kinetics
• In vivo efficacy studies assessing how therapeutic interventions modulate protein expression and downstream STAT signaling
• Preclinical development of next-generation therapies, including type I and type II kinase inhibitors, allosteric modulators, and mutant-selective agents
• Validation of gene therapy, antisense oligonucleotide, siRNA, and CRISPR-based strategies targeting mutant JAK2 expression
• Biomarker discovery and qualification linking protein-level endpoints to hematologic parameters such as hematocrit, leukocyte counts, and spleen volume
• Comparative cross-species studies translating findings from mouse models to human MPN specimens
• Generation of quantitative, publication-quality datasets for peer-reviewed manuscripts and regulatory submission packages

FAQ

Q: Can mutant JAK2 V617F protein be distinguished from wild-type JAK2 protein?

A: Direct protein-level discrimination is achieved through targeted LC-MS/MS using mutation-spanning peptides. In antibody-based workflows, mutation-specific antibodies may exhibit limited availability or specificity, so total JAK2 and phospho-JAK2 measurements are typically interpreted alongside JAK2 V617F allele burden determined by qPCR or digital PCR, providing an integrated genotype-protein assessment.

Q: What sample quantities are required?

A: Typical requirements are 20 to 50 micrograms of total protein per lane for Western blotting, 50 to 200 microliters of plasma or serum for ELISA, and 0.5 to 2 million cells for flow cytometric analysis. For sorted progenitor populations or other low-input samples, capillary immunoassay platforms can work with low microgram or even nanogram-level protein amounts.

Q: How should samples be prepared and shipped?

A: Protein lysates should be prepared in RIPA buffer supplemented with protease and phosphatase inhibitors, aliquoted, and frozen immediately at minus 80 degrees Celsius. Tissues should be snap-frozen in liquid nitrogen or dry ice. All frozen materials must be shipped on dry ice with temperature monitoring, and fresh samples for flow cytometry should be shipped at refrigerated temperatures in appropriate medium.

Q: Which tissues are most informative for JAK2 V617F studies?

A: Bone marrow and spleen are the most informative because they are the principal sites of malignant hematopoiesis and extramedullary disease in JAK2 V617F models. Peripheral blood is recommended for longitudinal monitoring, while liver and histologic sections provide complementary information on disease extension and fibrosis.

Q: What is the typical turnaround time?

A: Standard Western blotting and ELISA projects are generally completed within two to four weeks after sample receipt, depending on cohort size and panel complexity. Studies involving cell sorting, immunohistochemistry, or targeted mass spectrometry may require four to eight weeks.

Q: What deliverables are provided?

A: Deliverables include a comprehensive technical report containing raw and processed data, representative blot or assay images, standard curves and validation parameters, quantitative densitometry or concentration calculations, statistical comparisons between experimental groups, and methodological descriptions suitable for manuscript preparation.